Medibio: Continues to progress in June quarter
- Medibio (MEB) has provided its June quarterly update, announcing the company is sitting on a cash position of around $810,000
- In April, Medibio submitted a 510K application to the U.S. food and drug administration (FDA) for its sleep staging medical software, MEBsleep
- Medibio says it’s pleased to apply after experienced distributions caused by reorganisation and lockdown measures due to Cover-19
- MEBsleep is a medical software that analyses physiological signals obtained during sleep by polysomnography
- Medibo is currently awaiting FDA approval, which it expects to receive in August 2020
- The company will also apply for the CE Mark approval, which will allow MEBsleep to sold in Europe
